Related Experiment Video
Updated: Jun 3, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs
Fan Bu1, Lan Qin2, Zhengchi Lou3
1Department of Neurology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Drug Design, Development and Therapy
|June 2, 2026
Summary
Next-generation pharmacotherapy offers new hope for depression treatment, including rapid-acting agents and personalized approaches. Optimizing existing treatments and integrating novel therapies are key to improving outcomes for diverse patient populations.
Area of Science:
- Pharmacology
- Psychiatry
- Neuroscience
Background:
- Depressive disorders cause significant global disability, with many patients not achieving remission using current antidepressants.
- Treatment-resistant depression (TRD) and bipolar depression present challenges like delayed action, incomplete response, and tolerability issues with conventional monoaminergic strategies.
Purpose of the Study:
- To review next-generation pharmacotherapies for depressive disorders.
- To examine novel drug classes and mechanism-informed optimization of existing treatments.
Main Methods:
- A narrative review based on a targeted literature search of biomedical and psychological databases.
- Inclusion of regulatory documents, prescribing information, pharmacogenomic data, and real-world evidence.
Main Results:
- Next-generation agents include N-methyl-D-aspartate (NMDA) receptor modulators, dextromethorphan-bupropion, multimodal antidepressants, neuroactive steroids, psychedelic-assisted therapy, kappa-opioid receptor antagonists, and bipolar mood stabilizers.
- Optimizing current drugs involves repurposing, augmentation, combination therapy, and measurement-based care.
- Pharmacogenomics and clinical stratification are crucial for precision pharmacotherapy.
Conclusions:
- Advancing depression pharmacotherapy requires novel compounds and improved treatment selection, sequencing, monitoring, and tolerability management.
- A next-generation framework should integrate new drug classes with optimized use of established agents, considering unipolar depression, bipolar depression, and TRD heterogeneity.
Keywords:
bipolar depressiondepressive disordersneuroactive steroidspsychedelic-assisted therapyrapid-acting antidepressantstreatment-resistant depressionMore Related Videos
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...